Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Control portion sizes
Matinas BioPharma Holdings (NYSE American: MTNB) shares plunged 68% from $1.93 to 62 cents Thursday after the company slashed its workforce 80% and began exploring strategic options that include potential sale of its lead pipeline candidate MAT2203, the Phase III-ready oral formulation of amphotericin B, and a wind down and dissolution of the company
Most patients achieve substantial weight reduction over 6-12 months, with continued benefits for longer durations
However, the practical challenge emerges from gastrointestinal effects
GLP-1RAs and related incretin-based therapies contribute to sustained weight loss in obese individuals, which is accompanied by improvements in related comorbidities
US$ 27.42
US$ 26.18
US$ 23.81
